Clinical Trial Update: Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Gemzar (gemcitabine) and Alimta (pemetrexed) in patients with recurrent platinum-sensitive and platinum-res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 2 | Status: TERMINATED